Learning from the experience, we are increasingly proposing such a conservative approach in selected patients with a favorable profile, including a large function-based resection, beyond guidelines from grade 3 gliomas, IDH-mutant, as illustrated by the increase of the multidisciplinary decision of a watch-and-wait approach over time. The gene discussed is IDH1; the disease is central nervous system cancer.